ArticleBMC pediatrics2026
Dysregulated expression of the EMX2OS/miR-34c-5p/TBL1XR1 regulatory axis: a novel signature for severe community-acquired pneumonia in children.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular pathology of severe community acquired pneumonia (SCAP) stays undefined; EMX2OS displays dysregulated expression in inflammation-related conditions, meriting exploration of its SCAP role. This study sought to investigate the expression pattern and clinical significance of EMX2OS in SCAP.
methodsSerum samples were collected from SCAP patients and healthy controls. RT-qPCR was employed to measure expression levels of EMX2OS, miR-34c-5p, and TBL1XR1 in serum and in LPS-stimulated BEAS-2B cells. Cell viability was assessed using CCK-8 assay, apoptosis was evaluated by flow cytometry, and inflammatory cytokines TNF-α, IL-1β, and IL-6 were quantified by ELISA. Oxidative stress and ferroptosis markers including MDA, GSH, and iron were determined using commercial kits. Molecular interactions were verified by dual-luciferase reporter assay and RNA immunoprecipitation.
resultsSerum EMX2OS and TBL1XR1 were upregulated whereas miR-34c-5p was downregulated in SCAP patients; EMX2OS demonstrated diagnostic utility and served as a risk factor. In LPS-stimulated BEAS-2B cells, EMX2OS and TBL1XR1 increased while miR-34c-5p decreased, accompanied by reduced viability, enhanced apoptosis, elevated inflammatory cytokines, and aberrant oxidative stress and ferroptosis markers, all of which were reversed by EMX2OS silencing. EMX2OS bound directly to and negatively regulated miR-34c-5p, which in turn bound directly to and suppressed TBL1XR1. Rescue experiments revealed that miR-34c-5p inhibition partially restored cellular injury phenotypes under EMX2OS silencing, and additional TBL1XR1 knockdown reversed these effects.
conclusionsOur findings suggest that EMX2OS is associated with inflammation, oxidative stress, and ferroptosis in SCAP, potentially by sponging miR-34c-5p to upregulate TBL1XR1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.